IP Verse

Inhibition Of Hsd17B13 In The Treatment Of Liver Disease In Patients Expressing The Pnpla3 I148M Variation

Patent No. EP3695012 (titled "Inhibition Of Hsd17B13 In The Treatment Of Liver Disease In Patients Expressing The Pnpla3 I148M Variation") was filed by Regeneron Pharmaceuticals on Oct 11, 2018. The application was issued on Mar 8, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
STRAWMANDec 8, 2023CMS CAMERON MCKENNA NABARRO OLSWANG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3695012

REGENERON PHARMACEUTICALS
Application Number
EP18803806A
Filing Date
Oct 11, 2018
Status
Granted And Under Opposition
Feb 3, 2023
Publication Date
Mar 8, 2023
External Links
Slate, Register , Google Patents